Journal: Naunyn-Schmiedeberg's archives of pharmacology
This retrospective study analyzed 56 advanced NSCLC patients with EGFR mutations treated with Almonertinib, stratified by nutritional risk and malnutrition status.
Key findings include:
- Shorter median progression-free survival in patients with nutritional risk or malnutrition (12.6–12.8 months) compared to well-nourished patients (19.7 months).
- Shorter median overall survival observed in the malnutrition group compared to well-nourished patients.
- Objective response rates did not differ significantly between groups.
- Serum albumin was independently associated with higher rates of adverse reactions.
- Almonertinib was generally effective and safe regardless of nutritional status.
- Poorer outcomes in malnourished patients likely reflect disease progression influenced by nutrition rather than drug resistance.
- Mild to moderate anxiety was common, highlighting the need for psychological support during treatment.